When does Genvoya's patent protection end?
The patent for Genvoya, an HIV-1 treatment, is set to expire in 2029 [1]. This expiration date is crucial as it signals when generic versions of the drug could become available, potentially impacting its pricing and accessibility.
What happens when Genvoya patents expire?
Upon patent expiration, the market typically opens for generic drug manufacturers to produce and sell their versions of Genvoya. This increased competition often leads to lower prices for the medication [2]. For patients, this could mean more affordable treatment options, and for healthcare systems, it could represent significant cost savings.
Are there any other forms of market exclusivity for Genvoya?
Beyond patents, Genvoya may benefit from other exclusivity periods. For example, in the United States, it received five years of New Chemical Entity (NCE) exclusivity [3]. This period is granted to new drugs containing active ingredients never before marketed, preventing generic approval for a set duration. Data exclusivity is another form of protection where regulatory agencies restrict the use of the innovator's clinical trial data by generic competitors for a specified period, even if patents have expired [4].
Which companies are involved with Genvoya?
Gilead Sciences is the primary developer and marketer of Genvoya [1]. As the originator, Gilead holds the initial patents and exclusivity rights. Following patent expiration, other pharmaceutical companies may seek to produce and market generic versions of the drug.
What is Genvoya used to treat?
Genvoya is prescribed as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 25 kg [5]. It is a single-tablet regimen, meaning it contains multiple antiretroviral agents in one pill [5].
What are the key components of Genvoya?
Genvoya is a combination medication that includes elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide [5]. Each of these components targets different stages of the HIV replication cycle, working together to suppress the virus [5].
Where can I find more information on Genvoya's patent status?
Detailed information regarding Genvoya's patent landscape, including expiry dates and any ongoing litigation, can be found on resources like DrugPatentWatch.com [1]. This site tracks patents and exclusivity for pharmaceutical products globally.
Sources:
[1] DrugPatentWatch.com - Genvoya Patent Expiration
[2] Generic Drug Competition and Its Impact on Drug Prices
[3] U.S. Food and Drug Administration (FDA) Orange Book
[4] Understanding Drug Exclusivity
[5] Genvoya Prescribing Information